NL-OMON31631尚未招募2 期
A phase II study of carboplatin -paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. - ULCN-0107 Bevacizumab plus erlotinib beyond progression
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Advanced stage NSCLC (IIIB with malignant pleural effusion or stage IV) excluding squamous cell histology, with measurable or evaluable disease.
- •- No prior systemic therapy for advanced NSCLC, prior therapy for early stage disease with one regimen is acceptable if it was completed at least 6 months prior to study entry.
- •- Palliative radiotherapy to painful bony metastases will be permitted prior to study entry if completed prior to initiation of study treatment, and there are no residual sequelae of therapy such as bone marrow suppression.
- •- Life expectancy of at least 3 months.
- •- ECOG Performance status 0-1 (see appendix 2)
- •- Age 18 or higher.
- •-Female patients with reproductive potential must have a negative serum pregnancy test within 72 hours prior to start of study medication. All female patients of childbearing potential, and all male patients, must agree to use a medically acceptable method of contraception or agree to be abstinent throughout the treatment period and for 3 months after discontinuation of treatment
- •- Patients must have normal organ and marrow function
排除标准
- •- Prior systemic treatment for advanced NSCLC. One prior regimen (up to 4 cycles) of neoadjuvant or adjuvant therapy for early stage disease will be allowed if completed at least 6 months prior to study entry.
- •- Known brain metastases (in case of clinical signs or symptoms of brain metastases radiological evaluation is mandatory).
- •- Prior treatment with bevacizumab or erlotinib.
- •- History of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to bevacizumab or erlotinib.
- •- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in any other experimental drug study.
- •- Concomitant chemotherapy, radiotherapy or investigational agents.
- •- Evidence of bleeding diathesis or coagulopathy.
- •- Use of full dose anti-coagulant agents.
- •- Pregnant (positive pregnancy test) or lactating women.
- •- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start, anticipation of need for major surgical procedure during the course of the study.
- •- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to start.
- •- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to start.
- •- Serious, non-healing wound, ulcer, or bone fracture.
- •- Lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel, or with significant cavitation as assessed by treating investigator in consultation with an attending radiologist.
- •- History of hemoptysis (bright red blood of 2.5 ml or more).
- •- Significant co-morbidities including:
- •- No uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg)
- •- Unstable angina
- •- New York Heart Association (NYHA) Grade II or greater congestive heart failure
- •- History of myocardial infarction within 6 months
- •- History of stroke within 6 months
- •- Clinically significant peripheral vascular disease
- •- Patients diagnosed with a tracheo-oesophagal fistula
- •- Another active malignancy except for non-melanoma skin cancers in the last 5 years.
- •- Inability to comply with study and/or follow-up procedures.
研究者
相似试验
进行中（未招募）
不适用
A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. - bevacizumab plus erlotinib beyond progressioEUCTR2007-005523-15-NLRadboud University Medical Centre
已完成
2 期
A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancerThymic cancerJPRN-UMIN000001358West Japan Oncology Group40
进行中（未招募）
不适用
Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer, Phase 1b/2EUCTR2010-022240-21-HUIsis Pharmaceuticals Inc.118
已完成
2 期
Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussionon-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion in stage4JPRN-UMIN000013329Osaka Prefectural Medical Center for Respiratory and Allergic diseases20
已完成
2 期
Phase II study of Carboplatin plus nab-Paclitaxel for advanced non-small cell lung cancer patients with interstitial lung diseaseAdvanced non-small cell lung cancer with interstitial lung diseaseJPRN-UMIN000012989Kanagawa Cardiovascular and Respiratory Center90